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Abstract
Nowadays, direct-acting antivirals (DAA) have been used for hepatitis C virus (HCV) 
treatment leading to cure in 90–95% of non-cirrhotic patients depending on genotype, 
treatment experience, and regimen used. It was observed rates of antiviral response above 
90% in compensated cirrhotic patients that should be treated for long time and/or ribavi-
rin may be required. Metabolic syndrome, obesity, and insulin resistance are increasing 
worldwide and further contribute to hepatic steatosis and have long been recognized as 
a cause of lipid deposition in the liver. These factors affect the rate of antiviral response 
to interferon-based therapy, but it seems not impact DAA treatment. The effect of HCV 
eradication on hepatic steatosis and progression to fibrosis, cirrhosis, and hepatocellular 
carcinoma warrants further study in the era of direct-acting antivirals. Other factors that 
could be related to increase liver damage are vitamin D and associated polymorphisms. 
Patients with low concentration of total vitamin D [25(OH)D] presented high degree of 
fibrosis and high values of total cholesterol and triglycerides. In this chapter, we review 
the challenges and metabolic pathology associated with HCV infection and, discuss the 
influence of some metabolic factors which can cause liver damage.
Keywords: hepatitis C, metabolic syndrome, insulin resistance, vitamin D, genetic 
polymorphism
1. Introduction
Hepatitis C virus (HCV) infection is a serious health problem with an estimated 71 mil-
lion of people having chronic HCV worldwide [1]. During chronic hepatitis C (CHC), it 
is observed many extrahepatic manifestations that could lead to rapid progression of the 
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disease, increasing the risk of developing hepatocellular carcinoma (HCC) and advanced 
fibrosis [2, 3]. The effect of HCV eradication on hepatic steatosis and progression to fibrosis, 
cirrhosis, and hepatocellular carcinoma warrants further study in the era of direct-acting 
antivirals. Now, with HCV eradication possible in virtually everyone, the sequelae of ste-
atosis, fibrosis and its drivers will garner more attention. People infected by HCV genotype 
other than three presenting high BMI and visceral obesity have high risk of hepatic steatosis. 
It is believed that insulin resistance (IR) is the primary pathologic mechanism that leads to 
abnormal lipid accumulation within hepatocytes. But it is not defined if IR is due to host 
factors, presence of HCV infection, or a combination. These data become extremely relevant 
due to the high prevalence of obesity and metabolic syndromes observed worldwide [3].
Nowadays antiviral treatment for HCV demonstrated to be very effective (>90%), but it is 
important to recognize and identify irreversible and associated metabolic damage, thereby 
reducing the morbidity and mortality associated with HCV [3]. IR has been associated to CHC 
[4, 5], which is characterized by hyperinsulinemia in patients with normal fasting blood glu-
cose and with an increased risk of developing diabetes mellitus type II (DM2), heart disease, 
and nonalcoholic fatty liver disease [6–8].
One of the consequences of persistent IR may be the development of DM2. DM2 is a metabolic 
disease characterized by hyperglycemia that can occur due to defects in insulin secretion and/
or action involving specific pathogenic processes, such as the destruction of insulin-producing 
pancreatic beta cells or resistance to insulin action. It is the most common metabolic disease 
and the one with the highest prevalence among individuals with hepatitis C compared to 
those infected with the hepatitis B virus (HBV), for example [9, 10]. DM2 comprises approxi-
mately 90% of cases and may have a genetic and environmental component. Type 1 diabetes, 
comprising about 10% of the cases, results in the destruction of beta cells, which may lead to 
absolute insulin deficiency, thus requiring the exogenous administration of it to avoid keto-
acidosis and coma.
HCV core protein is involved in the development of IR, however little is known about the 
clinical impact of HCV core region on IR [11, 12]. Patients infected with HCV genotype 1b 
who had 70Q core mutation had higher rates of IR compared to those without the mutation, 
indicating that this substitution is associated with the development of IR [11]. Mutation at 
core 70Q have been associated to higher incidence of HCC and mutations in 70 and/or 91 core 
HCV are important predictors of IR in patients without cirrhosis or DM [13, 14]. However, 
this finding was not seen in Brazilian population [12].
Other factor that could be related to increase liver damage is vitamin D and associated poly-
morphisms. Vitamin D, whose active form is 1,25-dihydroxy vitamin D3, is essential for cal-
cium and bone homeostasis, and its deficiency has been associated to several diseases, such as 
cancer, cardiovascular and autoimmune diseases, IR, and infectious disease [15–19].
Vitamin D is an important immunomodulator and plays an important role in metabolic and 
inflammatory diseases in the liver, including HCV infection. Vitamin D deficiency is common 
in healthy worldwide populations [20]. Despite this, patients with liver diseases such as CHC 
are at substantially higher risk for hypovitaminosis D [15, 21, 22]. The polymorphism of the 
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vitamin D receptor (VDR) gene was associated with rapid progression to fibrosis [bAt haplo-
type (CCA)] among HCV patients [23]. This information together demonstrates the potential 
of VDR-vitamin D axis association in viral hepatitis and highlights the importance of vitamin 
D as an immunomodulator, indicating an association between vitamin D deficiency and the 
absence of sustained virological response (SVR) in patients with hepatitis C [24, 25].
Studies have found a relationship between vitamin D concentration and decreased response 
to antiviral treatment in hepatitis C patients with genotype 1, 2 and 3 in double therapy with 
peg-interferon (PEG-IFN) and ribavirin [15, 24]. Bitetto et al. [26] observed that the vitamin D 
concentration and polymorphism in rs12979860 of IL28B gene were independent predictors 
of response to treatment. Patients who did not present the CC (IL28B) and vitamin D defi-
cient genotype presented a greater risk of not responding to antiviral treatment. In addition, 
vitamin D concentration supplementation improves response to antiviral treatment in double 
therapy with PEG-IFN and ribavirin for recurrent hepatitis C [27]. Scalioni et al. [28] demon-
strated that patients with lower concentration of 25(OH)D presented high degree of fibrosis 
and higher values of total cholesterol and triglycerides.
Currently, studies have been conducted correlating vitamin D and SVR levels in patients 
under direct-acting antivirals (DAAs) treatment. Backsteadt et al. [29] evaluated the associa-
tion of vitamin D levels with cirrhosis in an HCV-infected cohort. In addition, they assessed 
pre-treatment vitamin D levels up to week 12. A higher prevalence of vitamin D deficiency 
was observed in cohorts of HCV-cirrhotic patients, but changes in vitamin D levels did not 
influence SVR rates [29]. Belle et al. [30] evaluated the impact of vitamin D levels in treatment-
naive genotype 1 patients and submitted to conventional double therapy (PEG-IFN + ribavi-
rin) in a French cohort. No impact was observed between vitamin D levels and response to 
antiviral therapy [30]. Studies have also evaluated genetic polymorphisms related to vitamin 
D cascade in Thai population and have observed that polymorphism in the DHCR7 gene may 
be a predictive marker of response to dual therapy (PEG-IFN + ribavirin) in a patient with 
HCV genotype 1 [31].
Egypt has the highest prevalence rate of HCV infection in the world, where hepatitis C is 
considered a major health problem. The standard treatment of HCV is combination therapy of 
PEG-IFN and ribavirin where SVR is only achieved in 30% of the patients. Due mainly to the 
adverse effects and cost of treatment, discontinuation of treatment is an important approach. 
In this way, Abdelsalam et al. [32] evaluated the association between vitamin D concentration 
and VDR polymorphisms with SVR acquisition, where the concentration of vitamin D, FokI 
and TaqI was considered as predictors for the antiviral response with the combination of 
pegylated interferon and ribavirin.
2. HCV disease progression in patients with metabolic alterations
Recently, epidemiological, clinical, and experimental studies have related HCV to liver steato-
sis and several metabolic derangements [33–35]. There is also evidence that HCV infection can 
induce IR through different mechanisms [34]. Insulin metabolism is affected by HCV directly 
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and indirectly leading to the production of several proinflammatory cytokines. The process 
of replication, assembly, and release of HCV from hepatocytes depend on close interactions 
with lipid droplets and host lipoproteins. The role of HCV in lipid metabolism of hepatocytes 
can lead to hepatic steatosis, especially in HCV patients infected by genotype 3 [36].
In genotype-1 patients, liver steatosis is directly related to metabolic factors including 
IR [37]. The impact of IR on the progression of liver disease has been debated and many 
evidence suggest that patients who have IR have a worse prognosis concerning multiple 
disease outcomes including progression of hepatic fibrosis and development of hepato-
cellular carcinoma [37]. Before the era of DAA for HCV infection treatment, IR also had 
an impact on treatment response, which has now been overcome by the high efficacy of 
these drugs. However, even with DAA treatment, IR is improved after the achievement 
of SVR [33].
There are several studies that analyze the association of HCV infection with IR and a meta-
analysis of 34 studies found a positive correlation between HCV infection and increased risk of 
DM2 in comparison to the general population in both retrospective and prospective studies [38].
Regarding the studies that evaluated response to HCV treatment with interferon-containing 
regimens, it was observed that attaining SVR was associated with the improvement of IR 
defined by a lower homeostatic model assessment (HOMA)-IR after treatment [39, 40]. In 
addition, among patients submitted to treatment, those with a lower HOMA-IR had a higher 
chance of SVR [41].
Many studies found an association between higher HOMA-IR and fibrosis as well as the asso-
ciation of hepatocellular carcinoma with IR. Petit et al. [42] studied 123 HCV infected patients 
to investigate the host and viral specific factors associated with diabetes mellitus and IR in 
chronic hepatitis C patients. In diabetic patients, a score F4 was one of the factors related to 
the presence of diabetes mellitus and in patients without diabetes the HOMA-IR of METAVIR 
F 0 and F1 patients was significantly different compared to F2 and F3/F4 patients. They con-
cluded that IR in non-diabetic HCV-infected patients was related to grading of liver fibrosis 
and occurred already at an early stage during HCV infection [42].
Hickman et al. [43] hypothesized that host metabolic factors might be associated with 
increased body mass index (BMI) and might play a role in liver disease progression. Thus, 
they studied 160 HCV patients at the time of liver biopsy and collected their serum for the 
assessment of the levels of insulin, c-peptide and leptin. They found that insulin was inde-
pendently associated to fibrosis (P = 0.046) but not inflammation (P = 0.83). In addition, serum 
leptin levels were not associated to stage of fibrosis. So, in HCV patients infected by any 
genotype, increasing circulating insulin levels may be a factor responsible for the association 
between BMI and fibrosis [43].
Cua et al. [44] confirmed the impact of IR on fibrosis where they found that increased steato-
sis was related to high viral load (p = 0.001) but was not related to fibrosis (p = 0.1) in HCV 
genotype 3 patients. In HCV genotype I, body mass index (p = 0.04) and HOMA-IR (p = 0.01) 
contributed directly to steatosis. HOMA-IR was independently associated to fibrosis for HCV 
genotype 1 (OR, 3.22; p = 0.02) and genotype 3 (OR, 3.17; p = 0.04). [44].
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Petta et al. [45] aimed to assess whether increasing degrees of IR, up to overt diabetes, were 
associated to steatosis and higher stages of fibrosis in patients with CHC resulting from geno-
type 1 HCV. About 201 genotype −1 HCV-infected patients were evaluated by liver biopsy 
and anthropometric and metabolic measurements, including IR, by the HOMA-IR (nondia-
betic patients were defined as insulin resistant if HOMA-IR was >2.7). They evaluated three 
different groups concerning IR profile: 96 patients were noninsulin resistant (group 1), 76 
were insulin resistant without diabetes (group 2), and 29 were diabetic (group 3). At multi-
variate analysis, fibrosis of >/=3 was independently associated with high necroinflammatory 
activity, low platelets, low cholesterol, high ferritin, and a high prevalence of IR. Diabetic 
patients were twice as likely to have severe fibrosis (60%) than those with IR but no diabetes 
(30%) (p = 0.006). This study concluded that in genotype 1 HCV infected patients, IR and overt 
diabetes are major determinants of advanced fibrosis, regardless of the degree of steatosis, 
mainly in the presence of severe necroinflammation.
Mohammed et al. [46] also concluded in a study that evaluated HCV infected patients com-
pared to control group of non-infected HCV patients that IR may increase the rate of fibrosis 
progression in non-diabetic patients with chronic HCV. They suggested that follow up of 
hyperinsulinemia by serial assessment of HOMA-IR in non-diabetic HCV infected patients 
may be a biochemical indicator for progression of liver fibrosis [46]. On the other hand, some 
studies found no association between insulin resistance and liver fibrosis, like the one from 
Carvalho et al. who concluded that patients with chronic hepatitis C have significant meta-
bolic alterations (hyperadiponectinemia and high HOMA-IR values) that are independent of 
HCV viremia and liver fibrosis [47].
Another issue that deserves discussion is the association of HCC and IR. Although the 
exact delineated mechanism is not yet established, there are some evidences to emphasize 
the involvement of HCV induced chronic inflammation, oxidative stress, IR, endoplasmic 
reticulum stress, liver steatosis and liver fibrosis in the progression of HCV chronic disease 
to hepatocellular carcinoma [48]. Possibly, IR is only one step involved among a complex 
interplay among factors that lead to HCC development. The impact of IR on HCC develop-
ment is possible related to the fact that HCV interferes with insulin signaling by degradation 
of insulin receptor substrate 1 (IRS-1) and IRS-2 by suppressor of cytokine signaling (SOCS) 
protein or PI3K/Akt/mTOR pathway. IRS-1 is inactivated by TGF-α and PI3K/Akt also [49]. 
Based on these facts, the early stage of chronic HCV infection with increasing steatosis and IR 
creates an environment to develop hepatocarcinogenesis.
To investigate the role of IR and serum adiponectin level in hepatocellular carcinoma associ-
ated with chronic hepatitis C. Hung et al. analyzed three groups of patients and found that 
diabetes mellitus was more prevalent among HCV patients (35.6%, n = 59) compared to those 
infected by hepatitis B virus (HBV; 12.7%, n = 63), and non-HBV, non-HCV patients (7.1%, 
n = 28). Among HCV patients, age, serum insulin, HOMA-IR, DM and male gender were 
independently associated with HCC. This result was similar even when diabetic individuals 
were excluded from the analysis [50].
Noteworthy, most studies that evaluated the association of IR and HCV fibrosis are transver-
sal studies. Longitudinal studies evaluating truly fibrosis progression and HCC development 
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in patients with and without insulin resistance are needed to better understand this link. 
However, in the new DAA era one must reevaluate the impact of IR in fibrosis progression 
since the elimination of the virus per se will probably improve liver histology as well.
3. HCV treatment in patients with metabolic syndrome and vitamin 
D deficiency
HCV infection may contribute to hepatic steatosis and to metabolic syndrome, forming a posi-
tive feedback that may further increase steatosis and culminate in steatohepatitis and fibro-
sis. As HCV infection is considered a curable disease, fibrosis can regress in some patients 
after therapy response [51, 52]. However, based on data from IFN era, infected patients have 
comorbidities, as metabolic syndrome, that may prevent fibrosis regression, leading eventu-
ally to a continued liver damage, even after viral eradication.
Vitamin D is an important physiological regulator that contributes to various biological, immu-
nological, and metabolic functions in liver diseases. Previous in vitro results indicated that 
25-OH vitamin D appeared to be significant associated with treatment response, particularly 
in the aspect of the rapid virological response (RVR) [53], which is an important predictive 
factor for SVR achievement [54, 55]. Patients with RVR have an approximately 90% of chance 
of treatment success after receiving PegIFN/RBV combined therapy, regardless of the viral 
genotypes [56–58]. The achievement of this early goal provides greater flexibility for tailoring 
the treatment duration on an individual basis and enhances the cost-effectiveness of treatment 
[55]. However, the impact of 25-OH vitamin D deficiency on RVR and the precise mechanisms 
underlying the inhibition of HCV replication were not thoroughly elucidated.
Some cross-sectional studies have shown associations between a higher 25-OH vitamin D 
level and response to therapy with PEG-IFN and ribavirin [15, 59, 60], while low levels are 
associated with poor response and its supplementation improves SVR rates. On the other 
hand, studies conducted in French HCV patients did not observed an impact of vitamin D 
levels in response to double therapy [30]. No causality can be established by cross-sectional 
studies and discordant results have been observed [61]. Associations may occur because 
healthier people are more exposure to sunlight and perform more physical exercises, which 
lead to a higher 25-OH vitamin D level. Also, chronic inflammation can shorten the half-
life of 25-OH vitamin D and hepatic production of vitamin D-binding protein is reduced in 
patients with advanced liver disease and this may accelerate vitamin D turnover. Indeed, 
some studies pointed that its level before antiviral therapy has no impact on the efficacy of 
antiviral therapy, regardless the genotype [62]. On the other hand, an Italian study found high 
frequency of vitamin D deficiency among decompensated cirrhosis showing that vitamin D 
may play a role in the development of infections in patients affected by liver cirrhosis [63].
Potential relationship of vitamin D gene pathway has been suggested in the pathophysiology 
of HCV infection. Studies conducted in Asian and Latin America population did not find 
an association of VDR gene polymorphism to SVR in double therapy [28, 64]. On the other, 
studies conducted among European patients infected by genotypes 1, 2 and 3 found that VDR 
gene polymorphisms are independently related to the response to Peg-IFN + RBV therapy in 
CHC. These differences could be related to genetic differences among these studies [65, 66].
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Few studies have evaluated the impact of vitamin D metabolism in therapy with direct-acting 
antivirals (DAAs). Recently, Cusato et al. [67] evaluated the impact of polymorphisms in 
genes (CYP27B1, CYP24A1, VDBP and VDR) related to vitamin D pathway on sofosbuvir and 
GS-331007 plasma levels in HCV mono-infected patients at 1 month of treatment. They found 
that genetic polymorphisms involved in vitamin D pathway influenced drug concentration. 
In future, it might be useful to understand if these polymorphisms can affect other DAAs 
concentrations; and to understand their role in the prediction of clinical variables, such as the 
probability to develop hepatocarcinoma or to influence the viral load decay.
High rates of early tumor recurrence were recently reported after therapy with DAAs in 103 
HCV-infected patients with prior HCC [68]. Despite therapy with DAAs, the occurrence of 
liver cancer could not be reduced in cirrhotic patients with SVR [69]. Recently, a study con-
ducted in Italy found an association of HCC risk factors to age, ribavirin administration, IL28B 
rs12979860 CC and previous treatments; VDR FokI CC, sex and insulin resistance were pro-
tective factors [67]. However, three distinct prospective cohorts showed no increased risk of 
HCC recurrence in 267 patients after DAA treatments [70]. Whether DAA treatments increase 
HCC occurrence or recurrence rates will remain a subject for debate until have emerged with 
a proper control arm to assess this important question [71].
With the efficacious DAAs regimens, comorbidities appear not to impair SVR. Long-term 
studies in very large patient cohorts treated with DAAs will elucidate the degree to which 
steatosis, steatohepatitis, and/or fibrosis reverse with SVR. The persistence of these comor-
bidities may prevent complete return to health in HCV-cured patients.
4. Conclusion
In conclusion, several metabolic alterations, such as, insulin resistance and DM2 have been 
observed among CHC patients. During double therapy with PEG-IFN and ribavirin, IR 
and vitamin D levels were important to define high successful rates of virological response. 
Nowadays, with the advent of DAAs, the rate of SVR have been increased, however high rates 
of early tumor recurrence were recently reported after therapy with DAAs. In addition, the 
role of vitamin D levels and genetic polymorphisms involved in vitamin D metabolism could 
be important predictors for viral response and evolution of clinical cases. Further studies 
should be necessary to confirm the impact of these factors during new antiviral regimens.
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